Introduction
Spine fusion surgery is quite common, with over 250 000 such procedures performed annually in the United States alone. The most common type of spine fusion is posterolateral lumbar intertransverse process arthrodesis. Yet, failure to achieve a solid bony union (nonunion or pseudoarthrosis) occurs in up to 30% of patients with single level fusions, and more frequently when multiple levels are attempted. 1, 2 This high nonunion rate reflects the relatively poor optimization of biomechanical and biological aspects of the fusion surgery. A nonunion of a spine arthrodesis often leads to unsatisfactory resolution of clinical symptoms, [3] [4] [5] and usually results in greater medical costs and morbidity, as well as the need for more surgeries.
Current attempts at optimization of spine fusion surgery have had limited success. One frequently used clinical approach to prevent nonunions has been to increase the stiffness of the spine motion segment that is being fused. This involves using external fixation such as bracing, which is uncomfortable for the patient, or internal fixation (eg screws, hooks, rods, plates, and cages), which adds time and risk to the surgery. Another method of improving the spine fusion success rate is to improve the biological milieu of the healing process. Patients are often required to stop smoking and surgeons are using autologous bone graft whenever possible. These steps have decreased the number of nonunions; however, they have not eliminated the problem. Nonunions still occur in 10-15% of patients. [6] [7] [8] [9] Clearly, other optimizations must be made to improve spine fusion, especially in situations where nonunion rates are known to be high. Such situations include patients with osteoporosis, the need for continued steroid use during the early postoperative period, or in revision fusion attempts.
It has been difficult to study the spine fusion process in the clinical setting for many reasons. It can be difficult to evaluate the success or failure of bone healing with noninvasive methods, 10 which is a major limitation in clinical studies. The clinical outcomes after spine fusion may be dependent on the success or failure of a solid bony union in certain situations; however, in others it may be unrelated. 11 The biological processes involved in spine fusion are time dependent and multifactorial. Thus, a realistic animal model is an important adjunct for studying individual factors involved in this complex process. 12 Several models are now available that have led to an improved understanding of the biology of spine fusion.
Osteoinductive molecule production strategies for spine fusion Until recently there have been two main strategies for producing osteoinductive proteins. The first strategy was developed by Marshall Urist who first described a process of extracting osteoinductive molecules from bone. The active molecules later became known as a family of proteins termed bone morphogenetic proteins (BMPs). 14, 15 This strategy involves extracting and partially purifying a mixture of proteins including BMPs from animal or human cortical bone. In addition to human BMP extracts prepared on a limited basis in the laboratory of Dr Urist, [16] [17] [18] there is one commercial source of extracted bovine BMP mixture known as NeOsteot (Centerpulse Biologics, Austin, TX, USA). The second strategy involves the use of recombinant human BMPs, which was enabled by the cloning of many of the BMP genes. 19, 20 Recombinant human BMP-2 (rhBMP-2, Genetics Institute, Cambridge, MA, USA) has been used extensively for in vitro and in vivo safety and efficacy studies. Another BMP for which extensive in vitro and in vivo data are available is recombinant human BMP-7 (rhBMP-7), otherwise known as osteogenic protein-1 (OP-1t, Stryker Biotech, Natick, MA, USA). 20, 21 These osteoinductive proteins when applied to the spine with a carrier can induce bone formation. The translation of successful results from early small animal studies to human clinical trials has been impeded by an underestimation of the dose step-up required to make bone in humans and the difficulty in identifying a suitable carrier material for the slower healing process in higher animals. 22, [23] [24] [25] These three osteoinductive proteins (extracted BMP, rhBMP-2, and rhBMP-7) are in various stages of clinical pilot and pivotal studies. RhBMP-2 has been approved by FDA for anterior lumbar interbody fusion when used in conjunction with a collagen sponge and titanium cage. Pilot and pivotal clinical studies have indicated that rhBMP-2 used in this manner is as effective as autologous bone. 26, 27 Pivotal studies for posterolateral lumbar fusion are ongoing with rhBMP-7. 28 The extracted bovine BMP preparation has been tested in pilot experiments and also proven to be capable of bone induction in humans. 29 There are some potential limitations related to the use of osteoinductive proteins to augment bone formation in the spine. The first issue is the requirement for unexpectedly higher doses in humans than those needed in animals. This dose scale-up resulted in increased cost, which could be prohibitive for multilevel spine fusions or deformity surgery which require large volumes of bone graft. Another issue is that BMP molecules are soluble and can diffuse away or become inactivated in vivo. 30 Therefore, a single administration dose strategy may have a very limited duration of action and may not be ideal in certain spine fusion applications. Perhaps, because of one or more of these factors, not all clinical trials have yielded equally successful results.
The interpretation of results from a clinical trial using OP-1 to promote healing of tibial nonunions has been controversial because the OP-1 device did not result in better healing than autogenous bone graft. 31 This is a significant contrast with other BMP studies, which have shown a higher union rate with BMP than autogenous bone graft alone in almost every animal model when the proper dose and carrier have been used. 31 In addition, the failure to include a control group with no graft material precludes obtaining definitive evidence that any effect on healing was attributable to either the autograft or the OP-1, because the fractures also underwent intermedullary rodding and preparation of the nonunion site. Clearly, these were difficult fractures, often with multiple previous attempts to achieve union, and therefore was an exceedingly challenging task for the OP-1. Definitive demonstration of efficacy can only be shown with clinical studies designed with all the necessary controls and in applications where spontaneous healing does not occur. 32, 33 Spine fusion by gene therapy
In the last 4 years, research has been conducted by several groups to develop a gene therapy approach to achieve bone formation and testing these strategies for spine fusion. Gene therapy is the newest method of osteoinductive protein delivery and therefore there are relatively few published studies at present. The concept of local gene therapy for spine fusion involves the delivery of the gene or complimentary deoxyribonucleic acid (cDNA) sequence for an osteoinductive factor rather than delivery of the protein itself. This approach is based on the premise that the production cost of extracted or recombinant proteins is significantly higher than that of DNA replication and the use of gene therapy may provide a more prolonged delivery of the desired signal solving one of the theoretical problems associated with administering a single bolus of osteoinductive protein.
The use of local gene therapy for bone formation represents a major departure from traditional gene therapy programs intended for genetic defects such as muscular dystrophy and cystic fibrosis, or cancer treatment. The treatment of these disorders requires either 100% of the affected cells to receive the gene cassette, prolonged gene expression (life long), or both to be successful. In contrast, using gene therapy to initiate the process of osteoinduction is comparatively simpler. Assuming that the gene is transduced into cells ex vivo or placed directly into a scaffold matrix, targeting is not a major obstacle. If the gene encodes for a secreted osteoinductive protein, then gene transfer efficiency may not be an issue since the factor can diffuse away and affect other cells that did not receive the gene, producing a bystander effect. Finally, based on the fact that most osteoinductive growth factors are given as a one-time bolus that is rapidly metabolized, the required time of expression of the osteoinductive gene is likely to be days or weeks to initiate bone formation, rather than the months or years required for cancer or genetic disorders.
Gene therapy strategy was first tested for bone formation using a plasmid containing the cDNA sequence coding for the 1-34 peptide of the parathyroid hormone (PTH) protein. This cDNA was placed into a collagen matrix forming a 'gene-activated matrix' (GAM), which resulted in bone formation. 34 Although PTH may not be the ideal molecule for local bone induction in ectopic or intramuscular sites, this study did Several research groups have worked with the human BMP-2 cDNA delivered with a replication-deficient recombinant adenoviral vector. The Ad-hBMP-2 construct when transduced into murine stromal, 35 C2C12 myoblasts, 36 primary muscle-derived cells, 37, 38 or mesenchymal progenitor cells 39, 40 induced bone when injected intramuscularly in rodent muscle beds, rodent critical sized skull defects, 41, 42 or in a mouse radial segmental defect models. 43, 44 A similar ex vivo approach has been successful using bone marrow cells in rat femoral defects, 45 but unsuccessful for spine fusion in rabbits. 46 A similar ex vivo gene therapy followed by cell transplantation exists with other BMPs. Adenoviral delivery of BMP-7 cDNA driven by the CMV promoter in COS7 cells produced bone when implanted into mouse muscle or dermal pouches. 47 Subsequent studies by the same group showed that BMP-7-transduced fibroblasts form bone in vivo after an endochondral phase. 48 A retroviral vector was used to transduce rabbit periosteal cells with the BMP-7 cDNA and was used to repair rabbit cranial defects successfully. 49 Adenovirus has been used to transfer the BMP-9 cDNA to mesenchymal stem cells to produce spine fusion in rats. 50 The above strategies require isolation and culture expansion of the target cells prior to transfection and implantation; however, in vivo gene therapy approaches have also been attempted. Direct gene therapy with injection of Ad-hBMP-2 was successful in forming bone in the triceps surae muscle of mice 51 and in immunedeficient rats, but not in immune-competent rats. 52 Adenoviral vectors containing BMP-2 or BMP-9 cDNA successfully induced bone in a mandibular defect model. 53 Ad-BMP-2 has been inconsistent for achieving percutaneous spine fusion in immune-competent rats. 54 Gene therapy for bone formation is still largely preliminary in nature. All of the experiments have been in vitro or with small animal models. The inflammatory response evoked by the required concentration of vectors such as adenovirus may explain the inconsistent results seen with spine fusion in immunocompetent animals. This may be another problem when attempting to scale up from rodents to primates. Even with gene therapy approaches, spine fusion appears to be an extremely challenging bone healing application. 55, 56 One potential limitation of using BMPs, even when delivered via local gene therapy, is the requirement that the correct responding cells be present and that these cells express adequate quantities of the specific BMP receptor. Target cells may not migrate into the surgical site for days or weeks after surgery and the amount of residual BMP may be variable. We began to pursue a strategy to identify an early intracellular activator of the bone induction pathway. If found, such a factor could be expressed in cells for longer periods of time using gene therapy, reduce the concern of inadequate surface receptors, and more efficiently control bone formation by more closely mimicking the natural sequence of events rather than the expression of a single BMP protein.
The discovery of LIM mineralization protein-1 (LMP-1) has provided an opportunity to develop a gene therapy approach using an intracellular activator of the osteoinductive cascade. LMP-1 is a novel intracellular LIM domain protein, which initiates membranous bone formation in vitro and in vivo when transfected into bone marrow buffy coat cells. 57 LMP-1 is an intracellular protein that acts via the secretion of a soluble osteoinductive factors. Multiple different BMPs have been implicated. The mixture of different BMPs have the potential to form heterodimeric BMPs, which can be much more potent than homodimeric BMPs. Owing to these advantages, LMP-1 does not require a high transfection efficiency and may be delivered without resorting to high-efficiency vectors that carry inflammatory/immune response as well as a more complicated regulatory approval process. The remainder of this article will focus on the series of critical decision steps in a translational gene therapy program using LMP-1 as an example. First, the discovery and mechanism of action of LMP-1 will be briefly reviewed.
Identification of a cDNA encoding a novel osteoinductive protein, LMP-1 Differential display PCR technique was used to identify novel genes expressed during early osteoblast differentiation. RNA from secondary rat osteoblast cultures stimulated to differentiate by glucocorticoid was compared with RNA from untreated control cultures and a DNA fragment with a novel sequence was identified (Figure 1 ). We then cloned and sequenced the entire cDNA of a novel intracellular protein, which was subsequently named LMP-1. LIM domain proteins are known to be important in cell growth and differentiation, but have not previously been reported in osteoblasts. 58 In situ hybridization of developing limb buds from mouse embryos showed that LMP-1 transcripts appeared at the time and place of transition from hypertrophic cartilage to primary trabecular bone during endochondral ossification, and were also seen in areas of membranous bone formation.
Determination of the function of LMP-1
When LMP-1 mRNA translation was blocked with antisense oligonucleotide, bone nodule formation and (Figure 2 ).
Critical decisions necessary for spine fusion gene therapy
In planning a gene therapy program for spine fusion, there are several critical decisions that must be made.
Once an osteoinductive gene is selected, the essential decision steps are as follows: (1) choice of delivery vector; (2) design of gene cassette construct; (3) establishment of the transduction conditions; (4) selection of the carrier matrix; and (5) establishment of in vitro and in vivo testing models.
Choice of delivery vector
The choice of delivery vector depends on the specific transgene being used to promote osteoinduction. If a gene that requires fairly high expression for a prolonged period of time is used, then a viral vector may be needed rather than naked DNA. Alternatively, if the transgene requires a relatively short expression time such as LMP-1 and can start a cascade, which is amplified in nontransduced bystander cells, then a DNA plasmid vector may be suitable. One must consider the safety profile of the vector at the dose that would be required for the particular gene candidate. 59 In one sense, the least risky vectors are DNA, 60 followed by nonintegrating viruses such as adenovirus, [61] [62] [63] and lastly by integrating viruses such as adeno-associated virus 64 and lentivirus. 65, 66 Another factor in safety is related to the immune response generated by the vector. Adenovirus can generate more of an immune response than other vectors such adeno-associated virus. Therefore, if a very high level of gene expression is required for a particular osteoinductive gene to be effective, then adenovirus may not be a suitable vector. Beyond safety, the mitotic status of the target cells determines whether retroviral vectors can be used. Finally, the suitability to practical clinical use must be considered. We will summarize our experience with delivering LMP-1 cDNA with a DNA plasmid vector. Bone marrow cells from rats were transfected ex vivo using SuperFect transfection reagent (Qiagen, Valencia, CA, USA) with pRC/CMV2-LMP-1 or the same vector with the gene inserted in the reverse orientation as a control. Transfected cells were implanted subcutaneously on a devitalized bone matrix carrier. Bone nodules formed by 4 weeks in the implants that expressed the LMP-1 gene; no bone was formed in the controls. 67 The same technique was used to perform posterior thoracic and lumbar spine fusions in rats. In all, 11 of 11 (100%) sites with the LMP-1 gene fused solidly, while 0/11 (0%) sites with the control gene (LMP-1 in the reverse orientation) formed any bone. 68 The bone formed by cells expressing LMP-1 was contained within the carrier and integrated directly onto the adjacent host bone. Normal osteoblast-lined trabeculae were seen with marrow elements in the implants transfected with LMP-1, but no new bone was formed in the control implants transfected with the control cDNA. These studies confirmed the feasibility of local gene therapy to generate spine fusion in vivo (Figure 3) .
While local bone formation for spine fusion is a onetime requirement at any particular level, the treatment of osteoporosis may require the longer-term delivery of osteoinductive molecules afforded by gene therapy technique. Applications involving regional or systemic bone induction, a vector that is efficacious in vivo, and capable of being easily dispersed over a wide area are ideal. For this purpose, we felt that a viral vector would be appropriate. Therefore, we have constructed a type 5 replication-deficient adenovirus containing the LMP-1 cDNA. This adenoviral-LMP-1 construct has proven to be osteoinductive in osteoblast cell cultures as well as in vivo in spine fusion experiments in rabbits. 69 
Design of gene cassette construct
The specific design of the transgene construct may have profound effects on the activity. We have found that Spine fusion by gene therapy ST Yoon and SD Boden although the 5 0 untranslated region of the therapeutic gene is not required, at least 50-100 base pairs are helpful -or at a minimum the 6-8 nucleotides just upstream from the ATG translation start site (Kozak sequence) are required for LMP-1 expression. [70] [71] [72] [73] [74] In addition to this upstream regulatory sequence that promotes ribosomal binding, the addition of a synthetic intron may enhance message stability and transgene expression, and this is currently under investigation.
Transduction conditions
Optimized gene transduction conditions can mean the difference between obtaining the desired physiologic effect and failing to induce bone formation. For DNA transfection, the key factors are dosage of DNA, choice of transfection mechanism, and time of transfection reaction. Maximizing osteoinductive gene expression is not always the desired strategy. Some genes (LMP-1 included) may have a physiologically appropriate range and fail to provide the desired effect if the level of LMP-1 expression is outside that range. Also, increasing the DNA dose or the amount of the transfection reagent may eventually result in cytotoxicity. We have preferred to use an ex vivo chemical transfection reagent such as SuperFect or Effectene (Qiagen) rather than electroporation, a gene gun, or an in vivo GAM (naked DNA) approach.
Work with an adenoviral LMP-1 construct has demonstrated an inverse relationship between infection time and viral dose. For example, in vitro bone formation in a rat osteoblast culture system is similar with an Ad-LMP-1 multiplicity of infection (MOI) of 0.25 for 10 min or an MOI of 0.0025 for 60 min.
Recently, the same rapid 10 min infection time paradigm translated into successful spine fusions using low-dose Ad5-CMV-LMP-1 in skeletally mature New Zealand white rabbits. 69 In this study, peripheral blood was successfully substituted for bone marrow as the source of buffy coat cells, making this strategy more practical for a clinical setting. All animals achieved a successful lumbar spine fusion without complications (Figures 4 and 5) .
At present, it is not clear why such a low dose of adenovirus with the LMP-1 cDNA is so effective. The explanation may be related to the signal amplification seen as a result of using an intracellular signaling factor. An important variable, in addition to MOI, is the absolute concentration of infectious particles per unit volume in which the infection is taking place. When dealing with such short infection times, a smaller infection volume may result in increased infection efficiency, and this phenomenon is currently under investigation. The low transduction efficiency required for LMP activity (MOIs less than 10) is below the sensitivity of common marker genes (eg b-galactosidase, green fluorescent protein). It is also unclear at present if the transduction of buffy coat cells is occurring through a mechanism other than the traditional adenoviral receptor. 
Carrier matrix
As with the use of recombinant or purified osteoinductive proteins, the choice of carrier matrix is paramount to successful bone formation. In a mechanically protected environment such as the inside of a rigid cylindrical fusion cage, a nonstructural carrier such as a highly resorbable collagen sponge may be adequate. In areas where there is no mechanical protection such as the posterolateral spine, a more rigid and resistant carrier is desirable. 23 This can be accomplished by using demineralized bone matrix, allograft bone, or ceramics to reinforce the carrier. The resorption timing of the carrier is also important to match the anticipated speed of osteoinduction. The final issue regarding carrier is the ability to detect osteoinduction via plain radiographs. Radiopaque carriers including the slower resorbing ceramics will preclude the easy visualization of new bone on plain radiographs. 75 Testing models: in vitro and in vivo It is extremely important to have model systems to work out the above variables to minimize animal use and maximize the chances of success upon initiating human clinical trials. We have adopted a strategy of first screening protocol changes in the rat osteoblast differentiation culture model. If the cell culture experiments are successful, we progress to rat ectopic implants with ex vivo transduction of buffy coat cells to confirm the results in vivo. However, it is important to understand that results in ectopic assays, especially in animals larger than rats, can be inconsistent based on the exact location on the trunk and may not be reflective of the healing environment near the spine. In addition, ectopic implants are rapidly resorbed and therefore must be explanted at the appropriate time for the animal being studied. As a result of the uncertainty with ectopic models in higher animals, it is critical to test any gene therapy program in an animal spine fusion model. We recommend beginning by screening factors in the rabbit posterolateral intertransverse process spine fusion model and progressing up to primates only when warranted by success in the rabbits. Once a consistent ability to form spine fusion is achieved, toxicity and biodistribution studies are required prior to proceeding onto phase I human clinical trials ( Figure 6 ).
Conclusion
We are currently at the beginning of a revolution in bone formation strategies. The older methods of forming new bone with xenograft, allograft, and autograft bone will inevitably become replaced by delivering osteoinductive molecules. Clinical studies have now provided definitive evidence that osteoinduction with BMPs in humans is possible and safe. The determination of appropriate carrier mechanical and biologic properties will prove to be increasingly critical. Despite early successes with exogenously applied osteoinductive proteins, investigators will continue to attempt to use gene therapy to deliver the cDNA for osteoinductive genes such as BMPs and LMP-1. Only time will tell which methods are both safe and effective as well as affordable for spine fusion. Once bone can be reliably formed using local gene therapy, further progress should enable regional and systemic bone formation with gene therapy, provided an inducible tissue-specific promoter can be identified. Finally, it is our belief that local, regional, and systemic bone formation represents ideal applications of gene therapy and may provide some of the earliest clinical successes of this promising technology. 
